Kerry becomes biotech leader

KERRY Group has become a bio-science company of world standing following its €355 million acquisition of Quest from ICI, Davy Stockbrokers believe.

Kerry becomes biotech leader

In a detailed research note on Kerry Group Davy Stockbroker's food analyst John O'Reilly argues that the purchase of Quest adds a whole new pharma dimension to Kerry Group.

Mr O'Reilly believes the acquisition of Quest's food ingredients business from ICI marks a significant point of departure in Kerry's strategy.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited